Zimmer Biomet Holdings (ZBH) has been the subject of various robust financial activities. Pacer Advisors recently reduced their stock holdings, while Boston Trust Walden Corp and Calamos Advisors LLC hold considerable positions in ZBH. The company is set to pay quarterly dividends in the third and fourth quarter of 2025. Zimmer Biomet's partnership with OneStep aims to provide enriched mobility data to enhance joint procedure recovery. The company's financial results for the third quarter of 2025 have been announced, as part of which their One-Off $304.6M loss has led to questions about margin trends. The company achieved FDA Clearance for an indexed version of ROSA® Knee Robotic Technology. ZBH's innovation push and lowered growth guidance are closely linked. The company announced the acquisition of Monogram Technologies and was granted FDA breakthrough designation for an Iodine-Treated Total Hip Replacement System. Amid all these, shares in ZBH were bought and sold by different asset management firms. The performance of the company amid financial results and various partnerships points towards its innovative approaches and sustainability in the healthcare sector.
Zimmer Biomet Holdings ZBH News Analytics from Mon, 05 May 2025 07:00:00 GMT to Thu, 01 Jan 2026 11:10:31 GMT -
Rating 0
- Innovation 6
- Information 7
- Rumor -2
